128 related articles for article (PubMed ID: 27713671)
1. Stability and Sterility of Enoxaparin 8 mg/mL Subcutaneous Injectable Solution.
Moffett BS; Dinh K; Placencia J; Pelkey G; Hui SR; Teruya J
J Pediatr Pharmacol Ther; 2016; 21(4):322-326. PubMed ID: 27713671
[No Abstract] [Full Text] [Related]
2. Anti-Xa stability of diluted enoxaparin for use in pediatrics.
Dager WE; Gosselin RC; King JH; Christensen CL; Owings JT; Larkin EC
Ann Pharmacother; 2004 Apr; 38(4):569-73. PubMed ID: 14982984
[TBL] [Abstract][Full Text] [Related]
3. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
4. Stability and sterility of diluted enoxaparin under three different storage conditions.
Summerhayes R; Chan M; Ignjatovic V; Prankerd R; Monagle P
J Paediatr Child Health; 2011 May; 47(5):299-301. PubMed ID: 21244553
[TBL] [Abstract][Full Text] [Related]
5. In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose.
Patel RP; Narkowicz C; Jacobson GA
Clin Ther; 2008 Oct; 30(10):1880-5. PubMed ID: 19014843
[TBL] [Abstract][Full Text] [Related]
6. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
7. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
8. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
[TBL] [Abstract][Full Text] [Related]
9. Sterility and Stability of Diluted Meloxicam in Compounded Multi-dose Vial after 365 Days.
Kawano HK; Simonek GD; Moffitt AD; Tahara JM; Brignolo AL
J Am Assoc Lab Anim Sci; 2019 Sep; 58(5):594-596. PubMed ID: 31383049
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
Hicks JK; Shelton CM; Sahni JK; Christensen ML
Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Spencer FA; Ball SP; Zhang Q; Liu L; Benoit S; Becker RC
J Thromb Thrombolysis; 2000 Apr; 9(3):223-8. PubMed ID: 10728020
[TBL] [Abstract][Full Text] [Related]
13. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
Moten MA; Gaber AO; Putney D; Patel SJ
Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
16. Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes.
Huffman J; Brown S; Lewis P; Lawson S; Ogle A; Peacock G
Int J Pharm Compd; 2018; 22(4):340-344. PubMed ID: 30021190
[TBL] [Abstract][Full Text] [Related]
17. Stability of chlorothiazide sodium in polypropylene syringes.
McCluskey SV; Gardner B; Graner KK; Vu N
Am J Health Syst Pharm; 2015 Aug; 72(15):1292-7. PubMed ID: 26195655
[TBL] [Abstract][Full Text] [Related]
18. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
19. Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method.
Feutry F; Simon N; Genay S; Lannoy D; Barthélémy C; Décaudin B; Labalette P; Odou P
Drug Dev Ind Pharm; 2016 Jan; 42(1):166-174. PubMed ID: 26006333
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
